Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

493 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Epstein-Barr Virus Orchestrates Spatial Reorganization and Immunomodulation within the Classic Hodgkin Lymphoma Tumor Microenvironment.
Yeo YY, Qiu H, Bai Y, Zhu B, Chang Y, Yeung J, Michel HA, Wright K, Shaban M, Sadigh S, Nkosi D, Shanmugam V, Rock P, Tung Yiu SP, Cramer P, Paczkowska J, Stephan P, Liao G, Huang AY, Wang H, Chen H, Frauenfeld L, Mitra B, Gewurz BE, Schürch CM, Zhao B, Nolan GP, Zhang B, Shalek AK, Angelo M, Mahmood F, Ma Q, Burack WR, Shipp MA, Rodig SJ, Jiang S. Yeo YY, et al. Among authors: cramer p. bioRxiv [Preprint]. 2024 Mar 7:2024.03.05.583586. doi: 10.1101/2024.03.05.583586. bioRxiv. 2024. PMID: 38496566 Free PMC article. Preprint.
SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized Trials.
Fisher LH, Kee JJ, Liu A, Espinosa CM, Randhawa AK, Ludwig J, Magaret CA, Robinson ST, Gilbert PB, Hyrien O, Kublin JG, Rouphael N, Falsey AR, Sobieszczyk ME, El Sahly HM, Grinsztejn B, Gray GE, Kotloff KL, Gay CL, Leav B, Hirsch I, Struyf F, Dunkle LM, Neuzil KM, Corey L, Huang Y, Goepfert PA, Walsh SR, Baden LR, Janes H; COVID-19 Prevention Network (CoVPN). Fisher LH, et al. JAMA Netw Open. 2024 May 1;7(5):e2412835. doi: 10.1001/jamanetworkopen.2024.12835. JAMA Netw Open. 2024. PMID: 38780941 Free article.
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.
Langerbeins P, Giza A, Robrecht S, Cramer P, von Tresckow J, Al-Sawaf O, Fink AM, Fürstenau M, Kater A, van der Spek E, Niemann CU, da Cunha-Bang C, Tausch E, Schneider C, Stilgenbauer S, Fischer K, Hallek M, Eichhorst B. Langerbeins P, et al. Among authors: cramer p. Am J Hematol. 2024 May 17. doi: 10.1002/ajh.27367. Online ahead of print. Am J Hematol. 2024. PMID: 38757754 No abstract available.
Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies.
Langerbeins P, Giza A, Robrecht S, Cramer P, von Tresckow J, Al-Sawaf O, Fink AM, Fürstenau M, Kutsch N, Simon F, Goede V, Hoechstetter MA, Niemann CU, da Cunha-Bang C, Kater AP, Dubois J, Gregor M, Staber PB, Tausch E, Schneider C, Stilgenbauer S, Eichhorst B, Fischer K, Hallek MJ. Langerbeins P, et al. Among authors: cramer p. Blood. 2024 Apr 15:blood.2023022564. doi: 10.1182/blood.2023022564. Online ahead of print. Blood. 2024. PMID: 38620092
Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial.
Fürstenau M, Giza A, Weiss J, Kleinert F, Robrecht S, Franzen F, Stumpf J, Langerbeins P, Al-Sawaf O, Simon F, Fink AM, Schneider C, Tausch E, Schetelig J, Dreger P, Böttcher S, Fischer K, Kreuzer KA, Ritgen M, Schilhabel A, Brüggemann M, Stilgenbauer S, Eichhorst B, Hallek M, Cramer P. Fürstenau M, et al. Among authors: cramer p. Blood. 2024 Apr 15:blood.2023022730. doi: 10.1182/blood.2023022730. Online ahead of print. Blood. 2024. PMID: 38620072
Three-step mechanism of promoter escape by RNA polymerase II.
Zhan Y, Grabbe F, Oberbeckmann E, Dienemann C, Cramer P. Zhan Y, et al. Among authors: cramer p. Mol Cell. 2024 May 2;84(9):1699-1710.e6. doi: 10.1016/j.molcel.2024.03.016. Epub 2024 Apr 10. Mol Cell. 2024. PMID: 38604172 Free article.
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.
Cramer P, von Tresckow J, Fink AM, Robrecht S, Giza A, Tausch E, Müller L, Knauf W, Zingerle M, Al-Sawaf O, Langerbeins P, Fischer K, Kreuzer KA, Kneba M, Wendtner CM, Stilgenbauer S, Eichhorst B, Hallek M. Cramer P, et al. Am J Hematol. 2024 Jun;99(6):1192-1195. doi: 10.1002/ajh.27304. Epub 2024 Apr 5. Am J Hematol. 2024. PMID: 38578022 Clinical Trial. No abstract available.
Good reasons for structural biology.
Cramer P. Cramer P. Nat Struct Mol Biol. 2024 Mar;31(3):393-394. doi: 10.1038/s41594-024-01232-7. Nat Struct Mol Biol. 2024. PMID: 38429440 No abstract available.
493 results